CCR2 and Marfan syndrome: Notably, Na Xu et al. have proved targeting CCR2 may be a potential medical therapy in both the early and late phases of MVD in MFS by using C-C chemokine receptor type 2 genetic knockout mice and C-C chemokine receptor type 2 antagonist RS504393 (40).